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Abstract
To assess imaging data in COVID-19 patients and its association with clinical course and survival and 86 consecutive patients 
(52 males, 34 females, mean age = 58.8 year) with documented COVID-19 infection were included. Seventy-eight patients 
(91%) were in severe stage of the disease. All patients underwent transthoracic echocardiography. Mean LVEF was 48.1% 
and mean estimated systolic pulmonary artery pressure (sPAP) was 27.9 mmHg. LV diastolic dysfunction was mildly abnor-
mal in 49 patients (57.6%) and moderately abnormal in 7 cases (8.2%). Pericardial effusion was present in 5/86 (minimal 
in size in 3 cases and mild- moderate in 2). In 32/86 cases (37.2%), the severity of infection progressed from “severe” to 
“critical”. Eleven patients (12.8%) died. sPAP and computed tomography score were associated with disease progression (P 
value = 0.002, 0.002 respectively). Tricuspid annular plane systolic excursion (TAPSE) was significantly higher in patients 
with no disease progression compared with those who deteriorated (P value = 0.005). Pericardial effusion (minimal, mild 
or moderate) was detected more often in progressive disease (P = 0.03). sPAP was significantly lower among survivors (P 
value = 0.007). Echocardiographic findings (including systolic PAP, TAPSE and pericardial effusion), total CT score may 
have prognostic and therapeutic implication in COVID-19 patients.
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Introduction
Outbreak of the newly emerged Coronavirus (SARS-CoV-2, 
COVID-19 disease) in late 2019 has been reported to involve 
multiple organ systems, including the cardiovascular sys-
tem. Initial reports from Wuhan, China in December 2019 
documented the presence of cardiac injury. Several hypoth-
eses were suggested for the mechanism of cardiac injury 
[1–3] and echocardiography has been advocated for manage-
ment of cardiac complications [4].
We conducted the current study to evaluate the potential 
role of echocardiography in detecting both significant and 
subtle structural or functional abnormalities in patients with 
documented COVID-19 infection and predicting patients’ 
outcome based on echocardiographic findings.
Methods
The study was performed in a high-volume COVID-19 refer-
ral center in Tehran, Iran. From March 5th 2020 to March 
27th 2020, we studied 86 consecutive COVID-19 positive 
with echocardiography. COVID-19 infection was confirmed 
by real-time reverse transcription polymerase chain reaction 
(rRT-PCR) from nasopharyngeal swabs. The study proposal 
was approved by the hospital ethical research committee. 
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Figure 1 shows the process of patient enrollment and their 
outcomes.
To describe the clinical picture of the patients, we clas-
sified them into 3 groups according to a published study 
from Wuhan, China—common, severe or critical [5]. The 
“common” group had fever, respiratory tract symptoms or 
evidence of pneumonia on imaging; the “severe” group had 
any of the followings: respiratory distress, resting respira-
tory rate ≥ 30/min, finger  O2 saturation ≤ 93%; and in the 
“critical” group, one of these conditions must have been 
present: intubation required for respiratory failure, the pres-
ence of shock or intensive care unit (ICU) admission due to 
multi-organ system failure. We defined shock as signs and 
symptoms of organ hypoperfusion in a patient with adequate 
preload status. Patient management and transfer to either 
general ward or ICU were guided by the hospital COVID-19 
protocol which was based on the national practice guidelines 
for SARS-CoV-2 management [6]. Radiologic assessment 
for hospitalized COVID-19 patients included chest X-ray 
and chest CT. A semiquantitative scoring system for expres-
sion of pulmonary involvement was used [7, 8] to score 
parenchymal involvement of each of 5 lung lobes (total CT 
score ranged from 0 to 25 for each patient).
The demographic, clinical, echocardiographic and chest 
CT data of patients were collected. All bedside echocardi-
ography studies were performed within the first 3 days of 
admission by two cardiologists who were responsible for 
the management of COVID-19 patients. Echocardiographic 
examination was performed with GE Vivid S5 ultrasound 
machine using standard personal protection equipment 
(PPE) for operator safety and only essential echocardio-
graphic data was collected including size and function of 
both ventricles, presence of pericardial effusion, significant 
valvular heart disease, LV diastolic dysfunction and esti-
mated systolic pulmonary artery pressure (sPAP). In Fig. 2, 
sample echocardiographic data that were measured and ana-
lyzed are shown. To analyze data, we classified the sever-
ity of LV systolic dysfunction into severe (LVEF ≤ 30%), 
moderate (LVEF = 31–44%) and mild dysfunction or normal 
(LVEF ≥ 45%).
Statistical analyses were performed using Statistical Prod-
uct and Service Solutions (SPSS) version 26.0 (IBM Corp, 
Armonk, NY). Descriptive variables were presented as fre-
quencies and percentages and continuous variables were 
described as mean (SD) values. Non-parametric variables 
were analyzed with Mann–Whitney U test. P value ≤ 0.05 
was considered significant.
Results
In the current study, 86 consecutive COVID-19 patients were 
included (Fig. 1). Among these, 52 (60.5%) were male and 
34 (39.5%) were female with mean age of 58.8 years (range 
16–86 years). The patients presented to the emergency 
department with dyspnea in 69 (80.2%), fever in 45 (52.3%), 
cough in 26 (30.2%), myalgia in 19 (22.1%) and chest pain in 
4 (4.7%) cases. The presenting clinical picture was “severe” 
in 78 (91%) and “common” in 8 (9%) patients. No patient in 
this study classified as “critical” stage at presentation. The 
two most common comorbidities were hypertension in 36 
(41.9%) and diabetes in 29 (33.7%). Demographic, clinical 
presentation and comorbidities of the study population are 
presented in Table 1.
Results of bedside echocardiography are shown in 
Table 2. Mean estimated LVEF was 48.1% (SD = 8.4%) and 
mean sPAP was 27.9 mmHg (SD = 6.1). LVEF was ≥ 45% in 
71 patients (82.6%), moderately reduced (LVEF = 31–44%) 
in 10 cases (11.6%) and severe (LVEF ≤ 30%) in 5 patients 
(5.8%). Based on American Society of Echocardiography 
86 consecutive confirmed COVID-19 patients 
underwent transthoracic echocardiography 
(March 5th 2020 to March 27th 2020)  
       Common Stage 
               8 (9%) 



















Fig. 1  The process of patient enrolment and outcomes
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(ASE) guidelines [9], LV diastolic function was reported as 
follows: normal in 29 (34.1%), grade 1 LV diastolic dysfunc-
tion in 49 (57.6%) and grade 2 LV diastolic dysfunction in 
7 (8.2%) patients. Data for LV diastolic function was not 
available in one case.
RV systolic function was reported as follows: normal in 
70 (81.4%), mild or moderate RV systolic dysfunction in 14 
(16.3%) and severe dysfunction in 2 patients (2.3%). Signifi-
cant valvular abnormalities included severe aortic stenosis 
(AS) in 2 (2.3%), moderate to severe AS combined with aor-
tic regurgitation in 2 (2.3%), moderate mitral regurgitation 
(MR) in 11 and severe MR in 1 (14.3%), moderate mitral 
stenosis in 1 (1.2%), moderate pulmonic insufficiency in 2 
(2.4%) and moderate tricuspid regurgitation in 11 (13.1%) 
cases. Pericardial effusion was not a common finding, mini-
mal to mild in 4 (4.7%) cases and moderate in only one 
patient (1.2%). Pulmonary hypertension was present only 
in seven cases (8.1%) and the maximum sPAP in our study 
was 50 mmHg.
DICOM files of chest CT scans were available in 50 
patients. In the remaining patients, chest CT scan had 
been performed in a referring center with no DICOM files 
available to review. Chest CT findings had ground-glass 
opacification in 27 (54%) and consolidation in 23 (46%). 
Chest involvement was bilateral in 46 (92%) patients. Mean 
total CT score was 7.46 (SD = 3.4) (Table 2).
Clinical deterioration to the next stage occurred in 32 
patients (37% of all cases) from severe to critical (Fig. 1). 
No patient in common stage progressed to a worse stage. 
No association was found between disease progression, 
LVEF and LV systolic dysfunction categories however 
total CT score was significantly higher in the group with 
the disease progression compared to the stable patients 
(9.06 vs 6.39, P = 0.002). Disease progression had a trend 
to occur more frequently in patients with LV diastolic 
dysfunction compared with patients with normal LV dias-
tolic function (P value = 0.052). Mean tricuspid annular 
plane systolic excursion (TAPSE) was higher in patients 
with no disease progression compared with those who 
deteriorated during their hospital course (mean TAPSE, 
22.17 mm vs 19.53 mm, P value = 0.005). Systolic PAP 
was significantly higher in patients with disease progres-
sion compared with clinically stable patients (mean sPAP, 
34.0 mmHg vs 26.2 mmHg, P = 0.002). Lastly, pericar-
dial effusion was detected significantly more frequently 
Fig. 2  Sample echocar-
diographic views and data that 
were obtained and measured in 
the study population includ-
ing parasternal long axis view 
(a), short axis views (b and c), 
apical four chamber view (d), 
assessment of LV diastolic func-
tion (e and f) and RV systolic 
function by TAPSE (g). TAPSE 
Tricuspid Annular Systolic 
Plane Excursion
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in initial echocardiography of patients who deteriorated 
during their hospital course (P value = 0.034) (Table 3).
The observed outcome was: 62 discharged cases 
(72.1%), 11 deaths (12.8%), and 13 patients with pro-
longed (more than 14 days) hospital stay (15.1%). Aver-
age length of stay in 73 patients with definite outcome 
(discharge or death) was 8.7 days.
Analyzing data from the mortality group (Table  4) 
showed that mean sPAP was significantly higher in 
the patients who died (mean sPAP, 32.78  mmHg vs 
27.32 mmHg, P value = 0.007). Moreover, mortality had a 
trend to occur more frequently in patients with LV diastolic 
dysfunction compared with patients with normal LV dias-
tolic function (P value = 0.055). The mortality group was not 
different from the surviving group in terms of total CT score. 
Although significant left sided valvular heart disease was not 
common in this study population, both cases with severe AS 
did not survive. sPAP was higher in patients with significant 
valvular heart disease (moderate or greater severity). Despite 
higher sPAP in patients with valvular heart disease, disease 
progression, mortality and CT score showed no significant 
difference in patients with and without significant valvular 
heart disease (P value = 0.44, 0.46, 0.87) respectively.
Gender was a discriminating factor in some aspects. 
Compared to men, women were younger (54.2 years vs 
61.9 years, P value = 0.030), had higher mean LVEF (50.1% 
vs 46.8%, P value = 0.045) and less LV diastolic dysfunc-
tion (P value = 0.036). Despite these differences, our analysis 
shows that gender has no effect either on mortality or disease 
progression. Total CT score had moderate correlation with 
hospital stay (P value = 0.003, r = 0.4).
Table 1  Demographic, clinical presentation and comorbidities of 
study population
CKD chronic kidney disease, COPD chronic obstructive pulmonary 
disease, CVA cerebrovascular accident, PCI percutaneous coronary 
intervention
Baseline characteristics Number (percent)
Mean age 58.8 years (16–86 years)
Female age 58.25 ± 19.36 years








 Chest pain 4 (4.7%)














Cigarette smoking 3 (3.5%)
COPD 3 (3.5%)
Heart failure 1 (1.2%)
Table 2  Bedside echocardiographic and chest CT data
GGO ground glass opacification, LVEF left ventricular ejection frac-
tion, sPAP systolic pulmonary artery pressure
Echocardiographic data (n = 86)
LV systolic dysfunction
 LVEF (%), mean ± SD 48.16 ± 8.46
 Normal and mild LV systolic dysfunction 71 (82.6%)
 Moderate LV systolic dysfunction 10 (11.6%)
 Severe LV systolic dysfunction 5 (5.8%)
LV diastolic function
 Normal 29 (34.1%)
 Grade 1 LV diastolic dysfunction 49 (57.6%)
 Grade 2 LV diastolic dysfunction 7 (8.2%)






Chest CT findings (n = 50)
 Total CT score, mean ± SD 7.46 ± 3.40
  Distribution
   Left sided 2 (4%)







   Highly suggestive 44 (88%)
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Discussion
Clarifying the pattern of organ involvement and disease 
progression course is one of the main foci of ongoing clini-
cal research about COVID-19. Although there are multiple 
reports on cardiovascular involvement in COVID-19 dis-
ease, limited data are available in determination of prognosis 
with early echocardiography in Corona virus infection. We 
conducted this single center study to evaluate initial imag-
ing data including echocardiographic features of COVID-19 
Table 3  Complete comparison of clinical and imaging data in patients with and without disease progression
CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident, GGO ground glass opacification, 
LVEF left ventricular ejection fraction, sPAP systolic pulmonary artery pressure, TAPSE tricuspid annular systolic plane excursion





Age (years), mean ± SD 54.46 ± 17.33 55.40 ± 22.54 0.306
Sex (male) 30 (57.7%) 22 (42.3%) 0.163
Comorbidities
 Diabetes 22 (75.9%) 7 (24.1%) 0.059
 COPD 1 (33.3%) 2 (66.7%) 0.285
 Smoking 4 (80%) 1 (20%) 0.404
 Hyperlipidemia 8 (88.9%) 1 (11.1%) 0.084
 CVA 2 (66.7%) 1 (33.3%) 0.888
 Cancer 1 (20%) 4 (80%) 0.062
 Coronary artery disease 13 (61.9%) 8 (38.1%) 0.560
 Heart failure 1 (100%) 0 (0%) 0.441
 CKD 4 (50%) 4 (50%) 0.337
 Hypertension 20 (55.6%) 16 (44.4%) 0.171
Echocardiographic data (n = 86) No progression
(n = 54)
Progression (n = 32) P value
LVEF (%), mean ± SD 52.31 ± 1.11 45.50 ± 5.26 0.160
 Normal/Mild LV systolic dysfunction 42 (59.2%) 29 (40.8%)
 Moderate LV systolic dysfunction 8 (80%) 2 (20%)
 Severe LV systolic dysfunction 4 (80%) 1 (20%)
LV diastolic dysfunction 31 (55.4%) 25 (44.6%) 0.052
sPAP (mmHg), mean ± SD 26.23 ± 3.91 34.00 ± 8.21 0.002
Pericardial effusion
 None 53 (65.4%) 28 (34.6%) 0.034
 Minimal 1 (33.3%) 2 (66.7%)
 Mild 0 (0%) 1 (100%)
 Moderate 0 (0%) 1 (100%)
TAPSE 22.17 ± 3.81 19.53 ± 3.90 0.005
Chest CT findings (n = 50) No progression (n = 30) Progression (n = 20) P value
Total CT score 9.06 ± 3.73 6.39 ± 2.72 0.002
Distribution 0.791
 Left sided 1 (50%) 1 (50%)
 Right sided 2 (100%) 0 (0%)
 Bilateral 27 (58.7%) 19 (41.3%)
Pattern
 GGO 16 (59.3%) 11 (40.7%) 0.569
 Consolidation 14 (60.9%) 9 (39.1%)
Result
 Intermediate 3 (50%) 3 (50%) 0.598
 Highly suggestive 27 (61.4%) 17 (38.6%)
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patients and to find any associations between these findings 
and the clinical course of the disease. Most of the patients 
(90.7%) in this study had severe form of COVID-19 disease 
and 37% of them experienced clinical deterioration.
Comparing patients who died with survivors, no statisti-
cally significant difference between mean LVEF and chest 
CT involvement were found. Only sPAP was significantly 
different between survivors and non-survivors. From echo-
cardiographic perspective, sPAP was higher and TAPSE 
was lower significantly in patients with disease progres-
sion. Patients with disease progression also had higher 
CT score and prevalence of pericardial effusion. Disease 
progression and mortality was not associated with comor-
bidities including diabetes, CAD and significant valvular 
Table 4  Complete comparison of clinical and imaging data in mortality and survivors’ group
CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident, GGO ground glass opacification, 
LVEF left ventricular ejection fraction, sPAP systolic pulmonary artery pressure, TAPSE tricuspid annular systolic plane excursion
Baseline characteristics (n = 86) Survivors (n = 75) Death (n = 11) P value
Age (years), mean ± SD 58.89 ± 15.33 58.82 ± 19.92 0.948
Sex (male) 47 (90.4%) 5 (9.6%) 0.20
Comorbidities
 Diabetes 27 (93.1%) 2 (6.9%) 0.208
 COPD 3 (100%) 0 (0%) 0.66
 Smoking 4 (100%) 0 (0%) 0.556
 Hyperlipidemia 9 (100%) 0 (0%) 0.273
 CVA 3 (100%) 0 (0%) 0.66
 Cancer 4 (80%) 1 (20%) 0.504
 Coronary artery disease 20 (95.2%) 1 (4.8%) 0.190
 Heart failure 1 (100%) 0 (0%) 0.872
 CKD 6 (75%) 2 (25%) 0.271
 Hypertension 32 (88.9%) 4 (11.1%) 0.478
Echocardiographic data (n = 86) Survivors (n = 75) Death (n = 11) P value
LVEF (%), mean ± SD 47.79 ± 8.88 50.68 ± 4.04 0.517
Normal/Mild LV systolic dysfunction 60 (84.5%) 11 (15.5%) 0.522
Moderate LV systolic dysfunction 10 (100%) 0 (0%)
Severe LV systolic dysfunction 5 (100%) 0 (0%)
LV diastolic dysfunction 46 (82.1%) 10 (17.9%) 0.055
sPAP (mmHg), mean ± SD 27.32 ± 5.88 32.78 ± 6.18 0.007
Pericardial effusion
None 71 (87.7%) 10 (12.3%) 0.274
Minimal 3 (100%) 0 (0%)
Mild 0 (0%) 1 (100%)
Moderate 1 (100%) 0 (0%)
TAPSE 21.4 ± 4.07 19.8 ± 3.61 0.258
Chest CT findings (n = 50) Survivors (n = 43) Death (n = 7) P value
Total CT score 7.31 ± 3.20 8.57 ± 4.80 0.361
Distribution
 Left sided 2 (100%) 0 (0%) 0.536
 Right sided 2 (100%) 0 (0%)
 Bilateral 39 (84.8%) 7 (15.2%)
Pattern
 GGO 23 (85.2%) 4 (14.8%) 0.593
 Consolidation 20 (87%) 3 (13%)
Result
 Intermediate 5 (83.3%) 1 (16.7%) 0.616
 Highly suggestive 38 (86.4%) 6 (13.6%)
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heart diseases. After Logistic Regression and adjustment 
of comorbidities, the association between sPAP and dis-
ease progression/mortality remained significant. When 
CT score was added to the regression model, association 
between sPAP and disease progression became non-signif-
icant, implying that sPAP was not an independent predic-
tor of disease progression. In other words, probably higher 
CT scores resulted in higher sPAP in these patients. We 
did not find an association between CT score and mortality 
in our study. This may be due to the number of patients 
(15.1%) with prolonged hospitalization (undetermined out-
come) at the time of data analysis. These findings under-
score the importance of pulmonary artery pressure and 
right ventricular function in the course of the COVID-19 
disease. An observational study by Hani M Mahmoud-
Elsayed was done to evaluate echocardiographic features 
of COVID-19 patients and its association with cardiac 
biomarkers. The two common echocardiographic abnor-
malities were RV dilatation and RV dysfunction while 
LV systolic function was normal in most of their patients 
[10]. Another retrospective study by William E. Moody 
showed RV systolic dysfunction is an independent pre-
dictor of all-cause mortality in COVID-19 infection [11]. 
One significant difference of our study with these two 
researches is the fact that in nearly fifty percent of their 
study participants, TR velocity and subsequently sPAP 
could not be measured by echocardiography. In a study 
by Szekely Y, systematic echocardiographic evaluation of 
one hundred COVID-19 positive patients showed LV sys-
tolic dysfunction is not a frequent finding (less than 10%) 
but RV dilation with or without RV systolic dysfunction 
is the dominant echocardiographic manifestation [12]. In 
a review by John F. Park multiple mechanism postulated 
to play role in the right ventricular dysfunction in these 
patients including increased after load due to acute respir-
atory distress syndrome and pulmonary embolism, cardio 
depressant effect of cytokines and direct viral injury to the 
right ventricle [13].
In the presenting study, LV diastolic dysfunction had a 
trend with mortality and disease progression in COVID-
19 patients but considering great concerns about higher 
prevalence of heart failure preserved EF (HFpEF) in 
patients with coronavirus infection [14], this issue needs 
to be clarified in future studies with larger sample size.
Echocardiographic data in stable COVID-19 patients is 
not helpful in many mildly ill patients, but in critically ill 
patients in ICU, attention should be directed to RV systolic 
function and differential diagnosis of pulmonary hyperten-
sion (e.g. pulmonary thromboembolism).
These imaging data have potential importance in clinical 
practice. Although performing routine echocardiography 
for COVID-19 patients is not reasonable due to operator 
safety, applying these data to clinical practice could include 
optimizing intra-vascular volume status along with treat-
ment of increased LV end-diastolic pressure (e.g. diuretics) 
in critically ill patients.
Limitations
1. This study was performed From March 18th 2020 to 
March 27th 2020. A defined protocol had not been 
implemented at that time in our hospital regarding time 
and interval of cardiac biomarker measurements (includ-
ing cardiac troponin and NT-proBNP) in COVID-19 
patients; Hence cardiac biomarker results were not avail-
able for all the study participants specifically in the first 
3 days of hospital admission.
2. The aim of this cross-sectional study was to detect any 
cardiac involvement in COVID-19 patients. Unfortu-
nately, there was no information regarding previous car-
diac status such as left and right systolic function in all 
the patients. Myocardial dysfunction that was detected 
in this group of patients were not necessarily related 
to COVID-19 disease and may be due to pre-existing 
cardiac disease, myocarditis or sepsis.
3. Performing follow-up echocardiography in the course of 
disease progression may have revealed later evidence of 
LV systolic dysfunction.
4. Most of the study population consisted of severe cases 
and generalization of our study results to less severely 
ill COVID-19 patients are not possible.
5. DICOM files of chest CT were not available for report-
ing in 36 patients
Conclusions
Role of echocardiography in management of COVID-19 
patients has not been fully defined. However, estimated sys-
tolic PAP, TAPSE measurement and pericardial effusion are 
parameters that should receive special attention in echocar-
diography. Other imaging data including total CT score may 
determine disease outcome.
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